D.C. biotech Vanda Pharmaceuticals acquires AnaptysBio’s drug for rare skin disorder
D.C.’s Vanda Pharmaceuticals Inc. has locked in a deal with a West Coast biotech to commercialize a drug for a rare skin ...
D.C.'s Vanda Pharmaceuticals battling FDA on multiple fronts
A D.C. drugmaker is fighting the FDA on multiple fronts, from trying protect its intellectual property from generic ...
H.C. Wainwright maintains $18 target on Vanda Pharmaceuticals stock
H.C. Wainwright reaffirmed their positive stance on Vanda Pharmaceuticals (NASDAQ:VNDA) with a Buy rating and a price target of $18.00, representing significant upside potential from the current price ...